Robert H. Chan

GSK R&D, Stockley Park
United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trial.

Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trial.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: April 02, 2025

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study.

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study.

Journal: Annals of medicine

Published: October 28, 2024

Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach.

Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach.

Journal: Clinical and translational allergy

Published: April 17, 2024

Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE.

Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE.

Journal: The journal of allergy and clinical immunology. Global

Published: January 08, 2024

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.

Journal: ERJ open research

Published: October 06, 2023

Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.

Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 08, 2023

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.

Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.

Journal: International forum of allergy & rhinology

Published: February 23, 2023

The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti-IL-5 Biologic Therapy.

The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti-IL-5 Biologic Therapy.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 06, 2023

Patient-Reported Outcome Measures for Severe Recurrent Bilateral Nasal Polyps: Psychometric Evaluation and Content Validity.

Patient-Reported Outcome Measures for Severe Recurrent Bilateral Nasal Polyps: Psychometric Evaluation and Content Validity.

Journal: OTO open

Published: October 18, 2022

Real-world characterisation of patients with chronic rhinosinusitis with nasal polyps with and without surgery in England.

Real-world characterisation of patients with chronic rhinosinusitis with nasal polyps with and without surgery in England.

Journal: Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery

Published: June 23, 2022

Elucidating the Real-World Burden of Chronic Rhinosinusitis With Nasal Polyps in Patients in the USA.

Elucidating the Real-World Burden of Chronic Rhinosinusitis With Nasal Polyps in Patients in the USA.

Journal: OTO open

Published: June 01, 2022

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.

Journal: Allergy

Published: March 10, 2022

Showing 1-12 of 35

Last Updated: 09/26/2026